Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer.

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...